Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 6.60Kopran Ltd, operating within the Healthcare Services sector, exhibits a mixed financial profile. The company demonstrates very strong solvency and growth, indicating a solid foundation and expansion. Profitability is also a notable strength, reflecting efficient operations and good returns. However, efficiency and financial ratios reveal areas needing attention. Liquidity is average, suggesting moderate short-term financial health. Overall, Kopran Ltd showcases robust growth and profitability, but could benefit from improvements in operational efficiency and financial management to achieve a more balanced and stronger financial standing. While showing good potential, the company's inconsistent financial metrics suggest the need for strategic adjustments to ensure sustained success.
Health Score : 6.60Kopran Ltd, operating within the Healthcare Services sector, exhibits a mixed financial profile. The company demonstrates very strong solvency and growth, indicating a solid foundation and expansion. Profitability is also a notable strength, reflecting efficient operations and good returns. However, efficiency and financial ratios reveal areas needing attention. Liquidity is average, suggesting moderate short-term financial health. Overall, Kopran Ltd showcases robust growth and profitability, but could benefit from improvements in operational efficiency and financial management to achieve a more balanced and stronger financial standing. While showing good potential, the company's inconsistent financial metrics suggest the need for strategic adjustments to ensure sustained success.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
34.54
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
40.82
P/B RATIO
1.98
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
1.36
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
-2.56
EV/EBITDA RATIO
15.35
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹217.58 as on Sep 1, 2026.
Growth Score : 10.00The company showcases very strong growth across all metrics. High revenue growth, operating profit growth, EPS growth, asset growth, and net income growth indicate robust expansion and market performance. This suggests effective strategies and strong market positioning. The healthcare industry benefits from consistent growth to meet increasing demand.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -2.85 | 15.27 | 11.62 | 2.44 | 8.1 |
| Operating Profit Growth Rate | 6.1 | -40.23 | 42.31 | -1.35 | -15.07 |
| Earnings Per Share (EPS) Growth | -11.1 | -55.37 | 87.08 | -24.41 | -33.29 |
| Asset Growth Rate | 39.18 | 6.38 | 14.31 | 13.59 | 7.58 |
| Net Income Growth Rate | -1.61 | -55.74 | 88.89 | -23.53 | -33.33 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.89 | Neutral | 98.00 | 43.88 | 88.00 |
| 3 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 4 | NGL Fine Chem Ltd | 6.98 | 34.11 | Neutral | 73.00 | 67.39 | 48.00 |
| 5 | Sakar Healthcare Ltd | 6.89 | 70.49 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 6 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 7 | Kopran Ltd | 6.60 | 40.82 | Undervalued | 62.00 | 6.30 | 26.00 |
| 8 | SMS Lifesciences India Ltd | 6.59 | 22.25 | Undervalued | 45.00 | 58.80 | 19.00 |
| 9 | Infinium Pharmachem Ltd | 6.42 | 33.97 | Neutral | 22.00 | 6.43 | 14.00 |
| 10 | Medicamen Biotech Ltd | 5.73 | 37.61 | Neutral | 20.00 | 6.94 | 10.00 |
| 11 | Albert David Ltd | 5.63 | -333.98 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | BPL Ltd | 5.46 | -28.58 | Neutral | -4.82 | -1.69 | -8.55 |
| 13 | Zim Laboratories Ltd | 5.41 | 108.20 | Neutral | 30.00 | 1.11 | 6.00 |
| 14 | Remus Pharmaceuticals Ltd | 5.31 | 27.61 | Neutral | 57.00 | 20.97 | 46.00 |
| 15 | Ind-Swift Laboratories Ltd | 4.95 | 77.18 | Neutral | 45.00 | 4.89 | 41.00 |
| 16 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 17 | Lyka Labs Ltd | 4.77 | -26.63 | Neutral | -4.00 | -8.93 | -10.00 |
| 18 | Wanbury Ltd | 4.65 | 27.30 | Neutral | 88.00 | 15.98 | 43.00 |
| 19 | Nectar Lifescience Ltd | 3.83 | -0.80 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Quarterly Report⬤22nd Jan 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT
Kopran Ltd is an Indian pharmaceutical company primarily engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage formulations (FDFs). With a strong focus on antibiotics, anti-ulcerants, and various therapeutic segments, it serves both domestic and international markets, operating two manufacturing facilities in Maharashtra.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Kopran Ltd's P/E ratio (TTM) is 34.54, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Kopran Ltd's P/B ratio is 1.98, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Kopran Ltd's P/S ratio is 1.36, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Kopran Ltd's PEG ratio is -2.56.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Kopran Ltd's EV/EBITDA ratio is 15.35.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Kopran Ltd's ROE is 4.91%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Kopran Ltd's ROA is 6.83%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Kopran Ltd's ROCE is 7%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Kopran Ltd's operating margin is 9.10%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Kopran Ltd's net margin is 3.82%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Kopran Ltd's current ratio is 1.48.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Kopran Ltd's debt-to-equity ratio is 0.03.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Kopran Ltd's interest coverage ratio is 4.40.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Kopran Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Kopran Ltd's EPS is -33.29.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹217.58. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1982
Headquarters: Mumbai, Maharashtra
Core Offerings: Active Pharmaceutical Ingredients (APIs), Finished Dosage Formulations (FDFs), Contract Manufacturing, Drug Intermediates
Stock Listing: NSE (KOPRAN), BSE (524280)
Promoter: Surendra Somani / Parijat Enterprises Private Limited
Founded in 1982, Kopran Ltd initially focused on Active Pharmaceutical Ingredients (APIs). Over the years, it expanded its operations into manufacturing and marketing of finished dosage formulations (FDFs) across various therapeutic areas like anti-infectives, gastro-intestinal, and pain management. The company has established two manufacturing facilities in India, obtaining approvals from various international regulatory bodies. It continues to serve both domestic and international markets for its diverse product portfolio.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients (API) | 57.1% | Operating Profit |
| Formulations | 42.9% | Operating Profit |
Active Pharmaceutical Ingredients (API): Manufactures a range of APIs, primarily focusing on anti-ulcerants and antibiotics. Operates a state-of-the-art API facility approved by various international regulatory authorities, catering to global markets.
Formulations: Produces a wide spectrum of finished dosage forms catering to therapeutic areas such as anti-infectives, gastro-intestinal, pain management, and cardiovascular. These products are sold in India and exported globally.
Mr. Surendra Somani (Chairman & Managing Director). A veteran in the pharmaceutical industry, he has been instrumental in the company's growth and strategic direction since its inception, overseeing its expansion into various segments.
Kopran Research Laboratories Ltd. (100% subsidiary)
Kopran (UK) Limited (Step-down subsidiary)
No major recent corporate actions on record.
The Kopran Ltd share price today is ₹217.58 on NSE (KOPRAN), as of 26 Sept 2026.
As of 25 Sept 2026, Kopran Ltd share price is ₹217.58, with previous close ₹217.58. Today's range is ₹217.58 to ₹217.58. The 52-week range is ₹107 to ₹287.20.
As of today, Kopran Ltd's market cap is ₹929.07 crore (Small Cap).
Kopran Ltd's current P/E ratio is 34.54, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 33.
Kopran Ltd's current P/B ratio is 1.98.
Kopran Ltd's current dividend yield is N/A. Last dividend of ₹0.50 per share was declared on 19-Sep-2023.
Kopran Ltd's EPS (TTM) is ₹-33.29.
Kopran Ltd is an Indian pharmaceutical company primarily engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage formulations (FDFs). With a strong focus on antibiotics, anti-ulcerants, and various therapeutic segments, it serves both domestic and international markets, operating two manufacturing facilities in Maharashtra.
Kopran Ltd is promoted by Surendra Somani / Parijat Enterprises Private Limited, holding 44.42% as of 25 Sept 2026.
Kopran Ltd is listed on NSE (KOPRAN) and BSE (524280). Its next quarterly results are expected on August 2024.
Adjusted Earnings Per Share (Adjusted EPS)
Dividend Per Share (DPS)
